Dioflan

Pharmacological properties

Dioflan has a venotonic and angioprotective effect, increases venous tone, reduces the extensibility of veins and venostasis, improves microcirculation, reduces the permeability of capillaries and increases their resistance, improves lymphatic drainage, and increases lymphatic outflow. Dioflan also reduces the interaction of leukocytes and endothelium, the adhesion of leukocytes in postcapillary venules, which reduces the damaging effect of inflammatory mediators on the walls and valves of the vein valves.

Pharmacokinetics T_½ is 11 hours. The excretion of the active substance of the drug occurs mainly through the intestine. With urine, an average of 14% of the dose taken is excreted.

Indications

Symptomatic treatment of venolymphatic insufficiency (edema, pain, heaviness in the legs). symptomatic treatment of hemorrhoids.

Application

For oral use.

Treatment of venolymphatic insufficiency (symptoms: swelling, pain, heaviness in the legs, night cramps, trophic ulcers, lymphedema). The recommended dose is 2 tablets per day: morning and evening with meals. After a week of use, you can take once 2 tablets per day with meals.

Treatment of chronic hemorrhoids. 2 tablets per day (in 2 divided doses) with meals. After a week of use, you can take 2 tablets per day once with meals.

Treatment of acute hemorrhoids: 6 tablets per day for the first 4 days and 4 tablets per day for the next 3 days. Apply with food. The daily number of tablets is divided into 2-3 doses.

A course of treatment. The duration of treatment depends on the indications for use and the course of the disease. The average duration of treatment is 2-3 months.

Contraindications

Hypersensitivity to the active substance or any of the components of the drug in history.

Side effects

Neurological disorders: dizziness, headache, malaise.

From the digestive system: diarrhea, dyspepsia, nausea, vomiting, colitis.

From the skin and subcutaneous tissue: rash, itching, urticaria, isolated swelling of the face, lips, eyelids, Quinckes edema.

The presence of yellow sunset FCF (E110) in the preparation may cause allergic reactions.

special instructions

The use of this drug in acute hemorrhoids does not replace specific treatment and does not interfere with the treatment of other proctologic diseases. in the event that within a short course of treatment the symptoms do not disappear quickly, a proctological examination should be carried out and therapy should be reviewed.

In case of impaired venous circulation, a more effective treatment is provided by a combination of therapy in compliance with the following lifestyle recommendations:

• avoid prolonged exposure to the sun, legs, overweight;
• walking and in some cases wearing special stockings to improve blood circulation.

Use during pregnancy and lactation. In pregnant women, the drug should be used with caution. Before use, consult a doctor. Studies have not revealed the teratogenic effects of diosmin, hesperidin and no side effects have been reported. Due to the lack of data regarding the penetration of the drug into breast milk, the use of the drug during lactation should be avoided. Studies of reproductive toxicity showed the absence of the effect of diosmin, hesperidin on rat fertility.

The ability to influence the reaction rate when driving vehicles or other mechanisms. The drug does not affect the ability to drive vehicles and work with different mechanisms. In case of signs of side effects of the drug (see ADVERSE EFFECTS), caution should be exercised.

Children. There are no data on the use of the drug in children.

Interactions

No interaction studies have been conducted. data on cases of interaction are not available.

Overdose

No cases of overdose have been reported.

Storage conditions

In the original packaging at a temperature not exceeding 25 ° C.